Clinical TrialsSearch results
Number of results: 568
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- Phase I/II study of hepatic arterial infusion chemotherapy of gemcitabine for unresectable cholangiocarcinoma (JIVROSG-0301)
- Unresectable cholangiocarcinoma
- Japan Interventional Radiology in Oncology Study Group (JIVROSG)
- 2005-08-07
Recruiting
- Phase1/2 study of endoscopic photodynamic therapy using ME2906 and ultrathin PDT probe in unresectable bile duct cancer
- Unresectable bile duct cancer
- Sato Junya
- 2023-01-16
Other
- Phase II study of Bevacizumab plus modified OPTIMOX1 in patients with unresectable advanced/recurrent colorectal cancer
- Unresectable advanced/recurrent colorectal cancer
- The Tokyo Cooperative Oncology Group
- 2008-06-01
Other
- Phase2/3 Study of OTS102 in Combination With Gemcitabine in Patients With Unresectable Advanced Pancreatic Cancer and Recurrent Pancreatic Cancer(PEGASUS-PC Study)
- Unresectable Advanced and Recurrent Pancreatic Cancer
- OncoTherapy Science, Inc.
- 2009-01-27
Other
- Establishment of surveillance system for the longstanding ulcerative colitis patients Comparative study of efficacy for the targeted biopsy and the step biopsy
- Ulcerative colitis
- Teikyo University School of Medicine
- 2009-01-05
Recruiting
- The Neural Basis of Higher-Order Cognitive Development in Childhood: An Investigation Using Functional Near Infrared Spectroscopy (fNIRS)
- Typical development
- HARADA Taeko
- 2022-10-18
Other
- Clinical study of combinational therapy of AD-4833 with metformin -Phase III double-blind comparative study-
- Type2 Diabetes
- Takeda Pharmaceutical Company Limited
- 2008-04-04
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Metformin
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Sulfonylurea
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2009-04-01
Other
- A Phase 2/3 Study of SYR-322 as an Add-on to a Thiazolidine
- Type 2 diabetes mellitus
- Takeda Pharmaceutical Company Limited
- 2008-10-01